Please assess the completion status of the following clinical trial:

Trial Title: Dietary Approaches to Stop Hypertension in 'Diastolic' Heart Failure 2 (DASH-DHF 2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Symptoms and/or signs of HFPEF in the past 12 months~* Most recent LVEF ≥ 50% (contrast ventriculography, echocardiography, nuclear scintigraphy)~* Diastolic dysfunction on previous echocardiogram/catheterization or evidence of abnormal neurohormonal activation (B-type natriuretic peptide (BNP) ≥ 100 pg/ml)~* History of systemic hypertension~* Willing to adhere to provided diet~Exclusion Criteria:~* NYHA Class IV heart failure symptoms~* Hospitalization for decompensated HF within past one month~* Uncontrolled hypertension (seated SBP ≥ 180 or DBP ≥ 110) at rest, on current antihypertensive regimen~* Changes in medical regimen for heart disease or hypertension within past 1 month, except diuretic dose adjustment (within past 1 week)~* Previous LVEF \< 40%~* Primary exercise limitation due to severe pulmonary disease~* Uninterpretable echocardiographic windows~* Worse than moderate mitral or aortic stenosis or insufficiency.~* Baseline serum potassium level \> 5.0 mmol/L or prior history of potassium \> 6.0~* Serum calcium/phosphorus product \> 50 at baseline~* Severe renal insufficiency (current estimated GFR \< 30 ml/min)~* Severe anemia (Hgb \< 9 g/dL)~* Severely uncontrolled diabetes mellitus (Hgb A1C \> 10%)~* Non-hypertension related cause of HFPEF (e.g. amyloidosis, sarcoidosis, constrictive pericardial syndromes, primary hypertrophic or restrictive cardiomyopathy)~* Primary right ventricular failure~* Myocardial infarction or unstable angina, including new or worsening anginal syndrome, within the past three months~* Uncontrolled arrhythmia (including non rate-controlled atrial fibrillation)~* Terminal illness expected to result in death within six months~* Psychiatric disorder or dementia with potential to compromise dietary adherence

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- DASH/Sodium-Restricted Diet Intervention (Type: ACTIVE_COMPARATOR): Each patient will eat 3 weeks of the provided DASH/SRD diet for 21 days. The diet is patterned after the intervention in the DASH-Sodium trial (Sacks FM et al. New Engl J Med 2001;344(1):3-10). The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants. At enrollment patients will be randomized to the DASH/SRD or Control Diet for 21 days and then cross over to the other for 21 days. Immediately following the provided DASH/SRD and Control Diet, patients will be instructed to adhere to the DASH/SRD for an additional eight weeks with dietary support.
- Control Diet Intervention (Type: ACTIVE_COMPARATOR): Patients will consume 3 weeks of a specially prepared diet that will be patterned on the information we collected using Food Frequency Questionnaires during our pilot study. The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants. At enrollment patients will be randomized to the DASH/SRD or Control Diet for 21 days and then cross over to the other for 21 days. Immediately following the provided DASH/SRD and Control Diet, patients will be instructed to adhere to the DASH/SRD for an additional eight weeks with dietary support.
- Healthy Control (Type: NO_INTERVENTION): Fifteen healthy age-matched and 10 young healthy control patients will be recruited. Age-matched healthy control subjects will undergo testing before and after 3 weeks of eating their habitual diet. Young healthy control subjects will only require 1 study visit with no dietary intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).